The first cases of Triojection, a system intended to produce ozone gas for spinal disc herniations and manufactured by Minimus Spine, were performed in Germany by Thomas Vogl, MD.
Here are five things to know:
1. Dr. Vogl is the director of the Institute for Diagnostic and Interventional Radiology at the J.W. Goethe University Hospital Frankfurt am Main. The cases were performed at the University of Frankfurt.
2. Dr. Vogl successfully completed 10 Triojection cases in December. "Triojection is unique in that it creates the ozone inside a sterile syringe and simultaneously measures the concentration of ozone within the syringe," said Dr. Vogl. "Early results have been favorable and I intend to continue with Triojection in my practice."
3. Intradiscal ozone gas injection has been used as an alternative to epidural steroids and surgical discectomy. The University of Frankfurt has been performing spinal ozone injections for over a decade.
4. In 2012, Dr. Vogl published a paper describing disc volume reduction following intradiscal ozone injection in 283 subjects with disc herniation. He is a listed author on more than 500 peer reviewed articles related to interventional radiology and currently sits on the editorial boards for the journals European Radiology and Academic Radiology.
5. After achieving successful European adoption of Triojection, Minimus Spine is positioning itself for sale to one of several medical device companies.
More articles on biologics:
Osteo-P bone graft substitute receives 510(k) clearance: 6 things to know
Watch out for spinal biologics in 2018 — 2 key thoughts from Dr. Roger Hartl